These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 22048815)

  • 21. Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.
    Massink MP; Kooi IE; van Mil SE; Jordanova ES; Ameziane N; Dorsman JC; van Beek DM; van der Voorn JP; Sie D; Ylstra B; van Deurzen CH; Martens JW; Smid M; Sieuwerts AM; de Weerd V; Foekens JA; van den Ouweland AM; van Dyk E; Nederlof PM; Waisfisz Q; Meijers-Heijboer H
    Mol Oncol; 2015 Apr; 9(4):877-88. PubMed ID: 25616998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition.
    Nagasawa S; Sedukhina AS; Nakagawa Y; Maeda I; Kubota M; Ohnuma S; Tsugawa K; Ohta T; Roche-Molina M; Bernal JA; Narváez AJ; Jeyasekharan AD; Sato K
    PLoS One; 2015; 10(2):e0118002. PubMed ID: 25679396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins.
    Myhre S; Lingjærde OC; Hennessy BT; Aure MR; Carey MS; Alsner J; Tramm T; Overgaard J; Mills GB; Børresen-Dale AL; Sørlie T
    Mol Oncol; 2013 Jun; 7(3):704-18. PubMed ID: 23562353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
    Melchor L; Honrado E; García MJ; Alvarez S; Palacios J; Osorio A; Nathanson KL; Benítez J
    Oncogene; 2008 May; 27(22):3165-75. PubMed ID: 18071313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.
    Heikkinen K; Rapakko K; Karppinen SM; Erkko H; Knuutila S; Lundán T; Mannermaa A; Børresen-Dale AL; Borg A; Barkardottir RB; Petrini J; Winqvist R
    Carcinogenesis; 2006 Aug; 27(8):1593-9. PubMed ID: 16474176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
    Weaver Z; Montagna C; Xu X; Howard T; Gadina M; Brodie SG; Deng CX; Ried T
    Oncogene; 2002 Aug; 21(33):5097-107. PubMed ID: 12140760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
    Riaz M; van Jaarsveld MT; Hollestelle A; Prager-van der Smissen WJ; Heine AA; Boersma AW; Liu J; Helmijr J; Ozturk B; Smid M; Wiemer EA; Foekens JA; Martens JW
    Breast Cancer Res; 2013 Apr; 15(2):R33. PubMed ID: 23601657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and pathologic aspects of basal-like breast cancers.
    Fadare O; Tavassoli FA
    Nat Clin Pract Oncol; 2008 Mar; 5(3):149-59. PubMed ID: 18212769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
    Johnson J; Choi M; Dadmanesh F; Han B; Qu Y; Yu-Rice Y; Zhang X; Bagaria S; Taylor C; Giuliano AE; Amersi F; Cui X
    Oncotarget; 2016 Nov; 7(46):75729-75738. PubMed ID: 27708239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic instability in breast cancer: pathogenesis and clinical implications.
    Kwei KA; Kung Y; Salari K; Holcomb IN; Pollack JR
    Mol Oncol; 2010 Jun; 4(3):255-66. PubMed ID: 20434415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival outcomes are associated with genomic instability in luminal breast cancers.
    King L; Flaus A; Holian E; Golden A
    PLoS One; 2021; 16(2):e0245042. PubMed ID: 33534788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying enhancer-driven subtype-specific prognostic markers in breast cancer based on multi-omics data.
    Zhao H; Zhang S; Yin X; Zhang C; Wang L; Liu K; Xu H; Liu W; Bo L; Lin S; Feng K; Lin L; Fei M; Ning S; Wang L
    Front Immunol; 2022; 13():990143. PubMed ID: 36304471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
    Yan M; Shield-Artin K; Byrne D; Deb S; Waddell N; ; Haviv I; Fox SB
    BMC Cancer; 2015 Jul; 15():506. PubMed ID: 26152113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients.
    Ronowicz A; Janaszak-Jasiecka A; Skokowski J; Madanecki P; Bartoszewski R; Bałut M; Seroczyńska B; Kochan K; Bogdan A; Butkus M; Pęksa R; Ratajska M; Kuźniacka A; Wasąg B; Gucwa M; Krzyżanowski M; Jaśkiewicz J; Jankowski Z; Forsberg L; Ochocka JR; Limon J; Crowley MR; Buckley PG; Messiaen L; Dumanski JP; Piotrowski A
    Hum Mutat; 2015 Nov; 36(11):1088-99. PubMed ID: 26219265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
    Tkocz D; Crawford NT; Buckley NE; Berry FB; Kennedy RD; Gorski JJ; Harkin DP; Mullan PB
    Oncogene; 2012 Aug; 31(32):3667-78. PubMed ID: 22120723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
    Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
    Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
    Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
    Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
    Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
    Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subtypes of familial breast tumours revealed by expression and copy number profiling.
    Waddell N; Arnold J; Cocciardi S; da Silva L; Marsh A; Riley J; Johnstone CN; Orloff M; Assie G; Eng C; Reid L; Keith P; Yan M; Fox S; Devilee P; Godwin AK; Hogervorst FB; Couch F; ; Grimmond S; Flanagan JM; Khanna K; Simpson PT; Lakhani SR; Chenevix-Trench G
    Breast Cancer Res Treat; 2010 Oct; 123(3):661-77. PubMed ID: 19960244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival differences of CIMP subtypes integrated with CNA information in human breast cancer.
    Wang H; Yan W; Zhang S; Gu Y; Wang Y; Wei Y; Liu H; Wang F; Wu Q; Zhang Y
    Oncotarget; 2017 Jul; 8(30):48807-48819. PubMed ID: 28415743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.